Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 1200
Single User License Price INR 84000
Hard Copy License Price USD 1200
Hard Copy License Price INR 84000
Corporate User License Price USD 1800
Corporate User License Price INR 126000
Request a Quote

Report Title

A-share Listed Active Pharmaceutical Ingredient (API) Companies-Profiles and Financial Data

Quote Request for License Type
License Type Price  
Single User License USD 1200
Hard Copy License USD 1200
Enterprise Wide License USD 1800
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

A-share Listed Active Pharmaceutical Ingredient (API) Companies-Profiles and Financial Data


Quote Request for License Type
License Type Price  
Single User License USD 1200
Hard Copy License USD 1200
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

A-share Listed Active Pharmaceutical Ingredient (API) Companies-Profiles and Financial Data

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

A-share Listed Active Pharmaceutical Ingredient (API) Companies-Profiles and Financial Data



Executive Summary

Active pharmaceutical ingredient (API) is a pharmaceutical substance or a mixture of pharmaceutical substances which becomes an active ingredient during the manufacturing. API can be applied clinically after it is processed into pharmaceutical preparation.

As one of the largest API manufacturers, China has established an integrated industrial system, after decades of development. CRI estimated that by the end of 2016, the number of chemical API manufacturers in China had exceeded 1,000, capable of producing 1,500 categories and 5 million tons of APIs.

CRI considers that China is the world's leading exporter of API and enjoys cost advantages compared with competitors. In the past decade, China's share of the global active pharmaceutical ingredient market has been increasing. China is the world's largest producer and exporter of API. Its production volume was over 3 million tons in 2016. Currently, the majority of chemical API companies in China are raw material suppliers, which gain the market share by scale and low costs and are weak in research and development.

CRI analyzed that China now enjoys advantages in API products in the global market. For example, antibiotic and bacteriophage, China-made penicillin, tetracycline and chloromycetin own price advantage. China is also the world's largest manufacturer and exporter of vitamin products, in which VC is the product with the biggest advantage. China's second-largest API exports are antipyretics and analgesics products. As the China's export price is 33.3% lower than the price in the international market, China-made citric acid and dexamethasone take a certain share in the global market.

In the global market of active pharmaceutical ingredient, except for the monopoly of some patented APIs, the market of general chemical API is perfectly competitive. Meanwhile, with the development of global pharmaceutical industry, the increasing demand of generic drugs and the change of API production patterns, international preparation manufacturers tend to outsource production, that is, purchasing APIs from API and preparation producers in developing countries. More and more API and preparation manufacturers in emerging markets, represented by China, India, Brazil and Russia, have been engaged in the supply and demand globally. As the world's largest producer and exporter of API, Chinese API enterprises are confronted with competition not only from domestic competitors but also from foreign enterprises, especially Indian companies. Therefore, China's API industry becomes increasingly competitive.

According to CRI, due to the rising labor cost and increasingly rigorous environment policies in China, the production cost of API has been lifted and consequently Chinese API could not maintain the price advantage. Therefore, the transfer to mid-high end market will be the future development trends of API.

In this report, CRI analyzes 30 API manufacturers listed in A-share market in China. The report provides readers with a quick guide to the profiles and financials of Chinese API manufacturers being listed in the recent 10 years.

The report is composed of two parts: the first part is enterprise profiles and the second part is the operation status of these enterprises in the recent decade (presently 2006 to 2016, we will update it to the latest as time goes by).

The operation status is demonstrated from the following perspectives: (1)financial indexes, such as earnings per share, book value per share (BPS), sales per share, net cash flow per share, return on net worth and debt to asset ratio; (2) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (3) indexes on the income statement, such as revenue, operating profit, net profit and EBIT; (4) indexes on the balance sheet, such as liquid asset, fixed asset, current liability, non-current liability, capital reserve and shareholders' equity.

(1) Financial Indexes

Earnings per Share

Book Value per Share (BPS)

Sales per Share (SPS)

Net Cash Flow per Share from Operations

Net Cash Flow per Share (CNY)

Return on Net Worth

Net Profit Margin on Total Assets

Return on Invested Capital (ROIC) (%)

Gross Profit Margin on Sales (%)

Net Profit Margin on Sales (%)

EBIT Margin (%)

EBITDA Margin (%)

Debt to Asset Ratio (%)

Total Asset Turnover (times)

Cash/Operating Income Received from Sales of Goods or Services

YOY Growth Rate of Operating Revenue (%)

YOY Growth Rate of Operating Profit (%)

YOY Growth Rate of Net Profit Attributable to Shareholders of Parent Company (%)

(2) Summary of Income Statement

Gross Revenue (CNY, million)

Total Operating Costs (CNY, million)

Revenue (CNY, million)

Operating Profit (CNY, million)

Total Profit (CNY, million)

Net Profit (CNY, million)

Net Profit Attributable to Shareholders of Parent Company (CNY, million)

Non-recurring Items (CNY, million)

Net Profit Deducting Non-recurring Items (CNY, million)

R&D Costs (CNY, million)

Earnings Before Interest and Tax (EBIT) (Based on iFind) (CNY, million)

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (Based on iFind) (CNY, million)

(3) Summary of Balance Sheet

Liquid Asset (CNY, million)

Fixed Asset (CNY, million)

Long-term Equity Investment

Total Assets (CNY, million)

Liquid Liability (CNY, million)

Non-current Liability (CNY, million)

Total Liability (CNY, million)

Capital Reserve (CNY, million)

Surplus Reserve (CNY, million)

Undistributed Profit (CNY, million)

Shareholders' Equity (CNY, million)

Equity Attributable to Shareholders of Parent Company (CNY, million)

(4) Summary of Cash Flow Statement

Cash Received from Sales of Goods and Services (CNY, million)

Cash Flow from Operations (CNY, million)

Cash Paid to Purchase Fixed Assets, Intangible Assets and Other Long-term Assets (CNY, million)

Cash Paid for Investments (CNY, million)

Cash Flow from Investments (CNY, million)

Cash Received from Investors (CNY, million)

Cash Received from Borrowings (CNY, million)

Cash Flow from Financing (CNY, million)

Net Increase of Cash and Cash Equivalents (CNY, million)

Cash and Cash Equivalents, End of Period (CNY, million)

Depreciation and Amortization (CNY, million)

Companies in the report:

1 Zhejiang Medicine Co., Ltd (600216.SH)

2 Zhejiang Hisun Pharmaceutical Co., Ltd (600267.SH)

3 Tianjin Tianyao Parmaceutical Co., Ltd (600488.SH)

4 Zhejiang Huahai Pharmaceutical Co., Ltd (600521.SH)

5 North China Parmaceutical Co., Ltd (600812.SH)

6 Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SH)

7 Zhejiang Starry Pharmaceutical Co., Ltd (603520.SH)

8 Northeast Pharmaceutical Group Co., Ltd (000597.SZ)

9 Apeloa Pharmceutical Co., Ltd (000739.SZ)

10 Shandong Xinhua Pharmceutical Co., Ltd (000756.SZ)

11 PKU HealthCare Corp., Ltd (000788.SZ)

12 Hubei Guangji Pharmaceutical Co., Ltd (000952.SZ)

13 Chengzhi Co., Ltd (000990.SZ)

14 Zhejiang NHU Co., Ltd (002001.SZ)

15 Yifan Pharmaceutical Co., Ltd (002019.SZ)

16 Zhejiang Jingxin Pharmaceutical Co., Ltd (002020.SZ)

17 Zhejiang Hisoar Pharmaceutical Co., Ltd (002099.SZ)

18 Guanfu Holdings Co., Ltd (002102.SZ)

19 Qianjiang Yongan Pharmaceutical Co., Ltd (002365.SZ)

20 Shenzhen Hepalink Pharmaceutial Group Co., Ltd (002399.SZ)

21 Changzhou Qianhong Bio-pharma. Co., Ltd (002550.SZ)

22 Xiamen Kingdomway Group Co., Ltd (002626.SZ)

23 Yantai Dongcheng Pharmaceutical Goup Co., Ltd (002675.SZ)

24 Shandong Jincheng Pharmaceutical Co., Ltd (300233.SZ)

25 Hebei Changshan Bio-pharma. Co., Ltd (300255.SZ)

26 Hunan Er-kang Pharmaceutical Co., Ltd (300267.SZ)

27 Chongqing Porton Pharmaceutical technology Co., Ltd (300363.SZ)

28 Zhejiang Garden Biochemical High-tech Co., Ltd (300401.SZ)

29 Anhui Sunhere Pharmaceutical Excipients Co., Ltd (300452.SZ)

30 Jiangxi Fuxiang Pharmaceutical Co., Ltd (300497.SZ)

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Single User License:
Only for single user or inner small group. The report cannot be printed or copied.

Corporate User License:
It can be used for all staff of the company. The report can be printed and copied.

Active Pharmaceutical Ingredients


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person